Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: scholarrock.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/28/2024 | $30.00 | Strong Buy | Raymond James |
10/25/2023 | $20.00 | Hold → Buy | Jefferies |
4/3/2023 | $26.00 | Overweight | Piper Sandler |
9/19/2022 | $30.00 | Buy | H.C. Wainwright |
7/12/2022 | $20.00 | Buy | Truist |
3/23/2022 | $24.00 | Buy | H.C. Wainwright |
12/22/2021 | $52.00 → $28.00 | Buy → Hold | Jefferies |
11/19/2021 | $56.00 | Overweight | Piper Sandler |
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13D/A - Scholar Rock Holding Corp (0001727196) (Subject)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
10-Q - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
10-Q - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
ARS - Scholar Rock Holding Corp (0001727196) (Filer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
3 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointment of Beth Shafer, Ph.D., to the newly created role of Chief Business Officer. Ms. Shafer brings over 20 years of biopharmaceutical industry leadership and expertise to Scholar Rock, where she will drive the Company's long-term corporate and business development strategy. "We are pleased to welcome Beth to the executive team at a transformative time for Scholar Rock," said Jay Backstrom, M.D., MPH, President and
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 7:00 a.m. ET on Thursday, September 5 in New York City. 2024 Wells Fargo Healthcare Conference: Scholar Rock management will participate in 1x1 meetings on Thursday, September 5 in Boston. A live webcast of
Scholar Rock (NASDAQ:SRRK, the "Company"))), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 85,200 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 48,685 shares of common stock and inducement restricted stock units, covering an aggregate of 36,515 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth
- Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in 4Q 2024 - New data from Phase 2 TOPAZ extension study in patients with nonambulatory SMA showed sustained clinical benefit over 48 months, a continued favorable safety profile with no new safety findings; patient retention rate of over 90% - Phase 2 EMBRAZE proof-of-concept trial enrolling ahead of schedule, topline data expected in 2Q 2025 - Presented new SRK-439 preclinical data at American Diabetes Association's 84th Scientific Sessions (ADA) supporting the potential to contribute to a favorable body composition; increased lean mass and reduced fat mass re
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its second quarter 2024 financial results and provide a business update on Thursday, August 8, 2024, at 8:15am ET. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Scholar Rock website at http://investors.scholarrock.com. To pa
Scholar Rock (NASDAQ:SRRK, the "Company"))), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards on July 10, 2024, covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 162,857 shares of common stock and inducement restricted stock units, covering an aggregate of 122,143 shares of its common stock. The company also announced that it granted inducement equity aw
- SRK-439, a myostatin inhibitor, is part of Scholar Rock's industry-leading anti-myostatin portfolio - Obesity program continues to progress, with first participants dosed in Phase 2 EMBRAZE trial of apitegromab in obesity Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin inhibitor,
Scholar Rock (NASDAQ:SRRK, the "Company"))), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 96,700 shares of its common stock to 5 newly hired employees, consisting of inducement stock options to purchase an aggregate of 55,258 shares of common stock and inducement restricted stock units, covering an aggregate of 41,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy SRK-181 combination with pembrolizumab was generally well tolerated Company holding conference call to discuss data with Dr. Toni Choueiri on Tuesday, June 4th at 7 a.m. CDT/8 a.m. EST Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein grow
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on Tuesday, June 4th at 7:00 a.m. CDT/8:00 a.m. EDT Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation
- Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointment of Beth Shafer, Ph.D., to the newly created role of Chief Business Officer. Ms. Shafer brings over 20 years of biopharmaceutical industry leadership and expertise to Scholar Rock, where she will drive the Company's long-term corporate and business development strategy. "We are pleased to welcome Beth to the executive team at a transformative time for Scholar Rock," said Jay Backstrom, M.D., MPH, President and
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 7:00 a.m. ET on Thursday, September 5 in New York City. 2024 Wells Fargo Healthcare Conference: Scholar Rock management will participate in 1x1 meetings on Thursday, September 5 in Boston. A live webcast of
Scholar Rock (NASDAQ:SRRK, the "Company"))), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 85,200 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 48,685 shares of common stock and inducement restricted stock units, covering an aggregate of 36,515 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth
- Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in 4Q 2024 - New data from Phase 2 TOPAZ extension study in patients with nonambulatory SMA showed sustained clinical benefit over 48 months, a continued favorable safety profile with no new safety findings; patient retention rate of over 90% - Phase 2 EMBRAZE proof-of-concept trial enrolling ahead of schedule, topline data expected in 2Q 2025 - Presented new SRK-439 preclinical data at American Diabetes Association's 84th Scientific Sessions (ADA) supporting the potential to contribute to a favorable body composition; increased lean mass and reduced fat mass re
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its second quarter 2024 financial results and provide a business update on Thursday, August 8, 2024, at 8:15am ET. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Scholar Rock website at http://investors.scholarrock.com. To pa
Scholar Rock (NASDAQ:SRRK, the "Company"))), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards on July 10, 2024, covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 162,857 shares of common stock and inducement restricted stock units, covering an aggregate of 122,143 shares of its common stock. The company also announced that it granted inducement equity aw
- SRK-439, a myostatin inhibitor, is part of Scholar Rock's industry-leading anti-myostatin portfolio - Obesity program continues to progress, with first participants dosed in Phase 2 EMBRAZE trial of apitegromab in obesity Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin inhibitor,
Scholar Rock (NASDAQ:SRRK, the "Company"))), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 96,700 shares of its common stock to 5 newly hired employees, consisting of inducement stock options to purchase an aggregate of 55,258 shares of common stock and inducement restricted stock units, covering an aggregate of 41,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy SRK-181 combination with pembrolizumab was generally well tolerated Company holding conference call to discuss data with Dr. Toni Choueiri on Tuesday, June 4th at 7 a.m. CDT/8 a.m. EST Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein grow
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on Tuesday, June 4th at 7:00 a.m. CDT/8:00 a.m. EDT Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 price target.
The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. The results from this trial will inform the development of SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity.
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $29 to $31.
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 price target.
Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patientsAnalysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategySRK-181 combination with pembrolizumab was generally well toleratedCompany holding conference call to discuss data with Dr. Toni Choueiri on Tuesday, June 4th at 7 a.m. CDT/8 a.m. ESTScholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT- Company will host conference call to discuss the data on Tuesday, June 4th at 7:00 a.m. CDT/8:00 a.m. EDTScholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation duri
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 price target.
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 price target.
Raymond James initiated coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $30.00
Jefferies upgraded Scholar Rock from Hold to Buy and set a new price target of $20.00
Piper Sandler resumed coverage of Scholar Rock with a rating of Overweight and set a new price target of $26.00
H.C. Wainwright resumed coverage of Scholar Rock with a rating of Buy and set a new price target of $30.00
Truist initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $20.00
H.C. Wainwright initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $24.00
Jefferies downgraded Scholar Rock Holding from Buy to Hold and set a new price target of $28.00 from $52.00 previously
Piper Sandler initiated coverage of Scholar Rock Holding with a rating of Overweight and set a new price target of $56.00
Credit Suisse resumed coverage of Scholar Rock with a rating of Outperform and set a new price target of $65.00
BMO Capital Markets reiterated coverage of Scholar Rock with a rating of Outperform and set a new price target of $79.00 from $54.00 previously